|Antibody & Protein Therapeutics Summit|
Antibodies in Oncology & Beyond
Antibody Drug Conjugates
Novel Protein Therapeutics
GTCbio is proud to present the 5th Novel Protein Therapeutics Conference to be held on July 11-12, 2017 in Baltimore, MD. This conference strives to connect industry and academic researchers in the protein therapeutics field to facilitate discussion on the current state of the industry and discuss recent studies and challenges involved in therapeutic development.
Representatives from big pharma, academic institutions and government research labs will present data and case studies on key topics including antibody drug conjugates, bispecific antibodies, antibody combinations, and check point inhibiting antibodies. Attend to learn and network with key opinion leaders in a highly interactive and intimate environment!
- Novel Protein Discovery Technologies
- Emerging Antigens, Neoantigens and Novel Therapeutic Targets
- Targeting Disease with Non-Antibody Scaffolds & Polyclonal Antibodies
- Advances in Antibody Engineering
- Regulatory Considerations to Bring Antibody Therapies to Market
We hope to see you there!
The 2017 Advisory Committee
|2017 Program Director|
|Victor-Jeffrey Leyton, Université de Sherbrooke|
|2017 Advisory Board Members|
|Neeraj Agrawal, Amgen|
|Ahuva Nissim, Queen Mary University|
|Amandeep Gakhal, Sutro Biopharma|
|Ann White, University of Southampton|
|Bill Harriman , Crystal Bioscience|
|Birgit Schoeberl, Merrimack Pharmaceuticals|
|Elad Firnberg, Revolve Biotechnologies|
|Ernesto Freire, Johns Hopkins University|
|Nicolas Fischer, Novimmune SA|
|Gregory Adams, Eleven Biotherapeutics|
|Janos Luka, Walter Reed Army Institute of Research|
|Matthew Robinson, Immunome, Inc|
|Michael R. Dyson, IONTAS Ltd|
|Andreas Pahl, Heidelberg Pharma|
|Pedro Berraondo López, CIMA, University of Navarra|
|Darren Schofield, MedImmune|
|Seema Kumar, EMD Serono|
|Jamshid Tanha, University of Ottawa|
|Thomas Pillow, Genentech|
|Medha J. Tomlinson, Abbvie|
|Yan Chen, Genentech|
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
NanoTemper Technologies develops, produces and markets innovative technologies and instrumentation used by thousands of scientists worldwide. The company stands for a strong commitment to quality and high-precision instrumentation made in Germany. The experienced team of experts focuses on users' benefits by ensuring maximum efficiency for research in pharmaceutical and biotechnology industries.
BSI is well known for its PEAKS software suite and service platform for proteomics discovery and therapeutic protein characterization by LC-MS. The benchmark de novo sequencing capabilities offers advanced solutions for proteomic and therapeutic protein discovery as provided through peptide/protein identification & quantification, peptide mapping, PTMs and sequence variants.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.